Hardman & Co Research: Shield Therapeutics (STX): Reassuring trading update
Shield Therapeutics (STX) is a commercial-stage company delivering specialty products that address patients’ unmet medical needs, with an initial focus on treating iron deficiency (ID) with ferric maltol. Feraccru/Accrufer has achieved regulatory approvals for both Europe and the US. The company has faced some unexpected challenges recently, but has not been overly affected by COVID-19. Having negotiated a good deal for the Chinese market, STX is seeing significant interest with respect to a US commercial partner, bringing the opportunity to launch into a >$1bn market. The cash runway for STX extends into 1Q’21.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.